Literature DB >> 29043829

Postpartum acute hemolytic transfusion reactions associated with anti-Lea in two pregnancies complicated by preeclampsia.

Marcia Marchese1.   

Abstract

CONCLUSIONS: Lewis blood group antibodies, which are mostly naturally occurring and considered clinically insignificant, have rarely been documented as a cause of acute hemolytic transfusion reactions (AHTRs). This report presents two cases of AHTRs caused by anti-Lea occurring in postpartum black females (one group B, one group AB) whose pregnancies were complicated by preeclampsia. Neither anti-Lea was detected by automated solid-phase red cell adherence technology in pre-transfusion testing. Therefore, red blood cell units, compatible by electronic crossmatch, were issued and transfused. The subsequent transfusion reactions were characterized by acute intravascular hemolysis, evidenced by both clinical and laboratory criteria. These two cases demonstrate that, even when least anticipated, hemolytic transfusion reactions may occur. As expected, neither live-born neonate was affected by hemolytic disease of the fetus and newborn. Because both transfusion reactions occurred in non-group O, postpartum black females with pregnancies complicated by preeclampsia, possible links between in vivo hemolytic anti-Lea, non-group O pregnant black females, and preeclampsia may require additional investigation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29043829

Source DB:  PubMed          Journal:  Immunohematology        ISSN: 0894-203X


  2 in total

1.  Incidence and risk factors of transfusion reactions in postpartum blood transfusions.

Authors:  Lars Thurn; Agneta Wikman; Magnus Westgren; Pelle G Lindqvist
Journal:  Blood Adv       Date:  2019-08-13

2.  Systematic sequence analysis of the FUT3 gene identifies 11 novel alleles in the Sindhi and Punjabi populations from Pakistan.

Authors:  Maomao Zhao; Atif Adnan; Allah Rakha; Shahid Nazir; Meihui Tian; Siyi Zhang; Hao Pang
Journal:  Sci Rep       Date:  2020-03-26       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.